[Immunohistochemical research on breast cancer cell proliferation and hormonal receptor status with special emphasis on HER-2/neu expression].
Breast cancer is the most frequent gynecological tumor. The HER-2/neu oncogene may play a role in the prognosis and management of patients with breast cancer. In a retrospective study on 100 patients, we correlated the expression of this oncogene with the classic clinical and pathological factors. 32 % of patients exhibited overexpression of HER-2/neu. There was no significant correlation with classic parameters. This finding could indicate that HER-2/neu expression is a new independent prognostic factor. Prospective studies correlating HER-2/neu overexpression with prognosis might provide additional data.
Ohlinger
R
R
Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Ernst-Moritz-Universität Greifswald.
Steffen
S M
SM
Oellig
F
F
Köhler
G
G
Schwesinger
G
G
Lorenz
G
G
D001943:Breast Neoplasms / Q000235:genetics / Q000473:pathology*; D002455:Cell Division; D005260:Female; D018734:Genes, erbB-2; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009367:Neoplasm Staging; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D011960:Receptors, Estrogen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*
D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone
Immunhistochemische Untersuchungen zum Proliferationsverhalten und Hormonrezeptorstatus bei Mammakarzinomen unter besonderer Berücksichtigung der HER-2/neu-Expression.